Biotech M&A rolls on as Alex ion snaps up Wilson for $855 mln
(Reuters) – Alex ion Pharmaceuticals has agreed to buy Sweden’s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of…
Medical studies in humans often launched on faulty evidence base
(Reuters Health) – New research reveals serious flaws in the animal studies that regulators and ethicists use to decide if an experimental drug should be tested in humans. Dr. Daniel…
Pfizer signs deal with Allogene to develop cancer cell therapy
(Reuters) – Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake,…
FDA refuses to review Alkermes’ depression treatment, seeks more trials
(Reuters) – Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval,…
Esperion’s drug clears study as add-on cholesterol treatment
(Reuters) – Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients, who were already on another treatment…
Biohaven plunges as investors pit migraine data against Allergan’s drug
(Reuters) – Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from…
Bolivian women weave devices to patch holes in hearts
(Reuters Health) – A team of Bolivian women are using indigenous Aymara weaving patterns to craft devices that can help repair heart defects, doctors involved in developing the device report…